制阻燃剂 (BFR) 对动脉样硬化机制的影响
Hai-Di Wu1, Li-Wei Yang2, Da-Yong Deng3
1Department of Cardiology, The First Hospital of Jilin University, Changchun 130021, China.
Ecotoxicology and environmental safety
|August 6, 2023
概括
制阻燃剂 (BFRs) 破坏内分泌功能并危害心血管健康. 本综述强调了BFRs作为动脉样硬化的危险因素,详细介绍了它们对血管细胞,脂质代谢和炎症的影响.
科学领域:
- 环境毒理学环境毒理学
- 心血管研究的心血管研究.
- 内分泌学 在内分泌学.
背景情况:
- 制阻燃剂 (BFR) 是普遍存在的具有内分泌干扰性质的环境污染物.
- 广泛暴露于BFR与多系统毒性有关,包括心血管影响.
- 通过各种机制,BFRs可能会导致动脉样硬化.
研究的目的:
- 审查BFRs的动脉样硬化机制.
- 专注于BFR对血管内皮细胞,脂质代谢,炎症和泡细胞形成的影响.
- 提出预防BFR诱导动脉样硬化的科学基础.
主要方法:
- 对BFR和动脉样硬化的实验数据和证据的文献综述.
- 分析BFR对基因表达和信号通路的影响.
- 专注于参与动脉样硬化发展的关键病理途径.
主要成果:
- BFRs可以增加心率,诱导心律失常,并导致心脏缩.
- 暴露于BFR与糖脂代谢障碍和血管内皮功能障碍有关.
- BFRs促进炎症反应和泡细胞的形成,有助于病前动脉样硬化变化.
结论:
- BFRs作为一种促动脉样硬化风险因素.
- 了解BFR的机制对于预防动脉样硬化至关重要.
- 需要进一步的研究来阐明BFRs在心血管疾病中的作用.
相关概念视频
Atherosclerosis I: Introduction
10
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
10
Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
13
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
Inflammation
53.9K
Overview
53.9K


